All News

2061 articles, sorted by publication time.

Biotech Industry · global

Lilly plans to acquire Merida for up to $2.875 billion, betting on therapies that remove disease-causing antibodies

Merida aims to change how autoimmune diseases are treated, moving from suppressing symptoms to directly removing the antibodies that drive disease. Lilly’s acquisition agreement brings resources to this development approach, but the lead drug remains in Phase 1 trials, and early signs of antibody reduction have yet to translate into clinical benefits.

Cancer Research · global

Where Do Dormant Breast Cancer Cells Hide? Tumor Map Reveals a Possible Protective Environment

The study links breast cancer cells’ activity states to their locations, finding that dormant regions often contain specific immune cells and fibroblasts. This offers clues for investigating cancer cells that remain after treatment, but how the “protective shield” forms and whether it could become a therapeutic target still require experimental validation.

Clinical Research · global

A Cell Therapy Signal in Refractory Rheumatoid Arthritis: Three of Six Trial Participants Remain in Drug-Free Remission

A single CAR T-cell infusion allowed some patients who had not improved despite multiple treatments to remain off arthritis medications during follow-up. This early trial also identified signs of changes in B-cell composition, but larger comparative studies are needed to determine how long the benefits last and what safety trade-offs they entail.

Synthetic Biology · global

Caffeine Makes Proteins Let Go: An AI-Designed Reversible Switch Explores a New Approach to Controlling CAR T Cells

Once cell therapies enter the body, how can their immune attack be reined in at the right time? A Texas A&M University team has designed a caffeine-controlled protein switch that reduces CAR T-cell activation in the laboratory, offering a new approach to adjustable therapies, though multiple challenges remain before clinical use.

Biotech R&D · global

Bringing Experimental Results Back to AI: Hansa Partners with Cradle to Design Protein Drugs for Autoimmune Diseases

The collaboration will enable protein design to address activity, stability and manufacturing requirements simultaneously, while continuously learning from Hansa’s experimental data. Whether it can shorten development timelines still requires laboratory validation; the promoted 18-month saving is not a result of this collaboration.